Key Stats for Danaher Stock
- Past-Week Performance: 7-%
- 52-Week Range: $171 to $242.8
- Current Price: $195.5
What Happened?
Danaher (DHR), a $24.6 billion life sciences and diagnostics tools company emerging from a two-year post-pandemic bioprocessing slump, just committed $9.9 billion to acquire Masimo, a gold-standard patient monitoring device maker, as its bioprocessing recovery accelerates toward high single-digit growth in 2026.
On February 17, Danaher announced it would pay $180 per share for Masimo, a 38.3% premium, expanding its Diagnostics segment with Masimo’s pulse oximeters and non-invasive monitoring devices while projecting $125 million in cost synergies and 15 to 20 cents of adjusted EPS accretion in the first full year post-close.
Danaher’s bioprocessing business, which supplies the filters, bioreactors, and consumables that drugmakers use to manufacture biologic medicines, delivered 7-9% growth in Q4 2025 and recorded its third consecutive quarter of sequential equipment order growth, the clearest sign yet that the post-pandemic inventory hangover has ended.
On January 21, Cepheid, Danaher’s rapid molecular diagnostics unit, received FDA clearance for the Xpert GI Panel, a test that detects 11 gastrointestinal pathogens from a single patient sample, extending a nonrespiratory menu already growing at low double digits.
CEO Rainer Blair stated at the TD Cowen Healthcare Conference on March 3 that “we really do see the LRP as well as double-digit earnings growth as a part of our future,” citing the company’s ability to deliver high single-digit EPS growth and 100 basis points of margin expansion even at the low end of its 3% to 6% core revenue guidance.
With global biologic revenues surpassing small molecule drugs for the first time in 2025, biologics on track to represent more than 2/3 of the top 100 drugs by 2030, a $8.35 to $8.50 FY2026 EPS guide, and Masimo set to close in H2 2026, Danaher’s recovery is compounding on multiple fronts simultaneously.
Wall Street’s Take on DHR Stock
The Masimo acquisition’s projected 15 to 20 cents of first-year EPS accretion, closing in H2 2026, arrives precisely as Danaher’s organic bioprocessing recovery drives consensus EPS from $7.80 to $8.41, layering inorganic growth onto an already-inflecting earnings base.
EPS troughed at $7.48 in FY2024 after a post-pandemic bioprocessing collapse and recovered to $7.80 in FY2025, with consensus projecting $8.41 in FY2026, a 7.8% step up as bioprocessing consumables grow high single digits and EBIT margins expand from 28.2% to 28.9%.
EBITDA, the broadest measure of Danaher’s operating cash generation across its life sciences and diagnostics portfolio, grew 6.6% to $7.69 billion in FY2025 and is projected to expand further to $8.19 billion in FY2026, with margins recovering from a post-pandemic low of 30.2% in FY2024 back toward 31.9%.
With 18 buys, 4 outperforms, 3 holds, and zero sells among 25 covering analysts, the Street is as unanimously constructive on DHR as it has been in years, with a mean price target of $264.91 implying 35.5% upside from the March 6 close of $195.50.
The spread between the $220 low target and the $310 high target maps directly to the two biggest variables in the story: bears require proof that the Masimo integration delivers its $125 million in cost synergies without disturbing Danaher’s core life sciences margins, while bulls price in bioprocessing equipment inflecting above flat guidance as reshoring CapEx accelerates.
What Does the Valuation Model Say?
The TIKR mid-case prices DHR at $307.43 by December 31, 2030, implying a 57.3% total return and a 9.8% annualized IRR, built on a 6.4% revenue CAGR and net income margins expanding from 22.7% in FY2025 to 25.2% in the mid case. The margin expansion assumption is directly supported by management’s guidance for 100 basis points of operating margin expansion even at the low end of its 3% to 6% core revenue growth range.
The market is pricing DHR as if the post-pandemic slump is ongoing, but EPS already inflected positive in FY2025 and the bioprocessing order book has grown for three consecutive quarters.
Three consecutive quarters of sequential equipment order growth in bioprocessing, the capital-intensive segment that collapsed through FY2023 and FY2024, provides the forward revenue evidence the TIKR model’s 6.4% revenue CAGR requires.
CEO Rainer Blair confirmed at the TD Cowen Conference on March 3 that pharma CEOs had made no changes to reshoring investment plans despite tariff uncertainty, validating the multi-year bioprocessing CapEx cycle the TIKR model prices in.
If the Masimo acquisition faces regulatory delays past H2 2026 or integration costs exceed the $125 million synergy target, the EPS accretion assumption breaks and the FY2026 guide of $8.35 to $8.50 comes under pressure.
Q1 2026 earnings will be the first post-Masimo-announcement read on whether bioprocessing consumables hold high single-digit growth and whether the $8.35 to $8.50 full-year EPS guide remains intact.
Should You Invest in Danaher Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up DHR stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Danaher Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze DHR stock on TIKR for Free →
